MX2020007467A - Metodo para solubilizar 5 amino 2,3 dihidroftalazin 1,4 diona. - Google Patents

Metodo para solubilizar 5 amino 2,3 dihidroftalazin 1,4 diona.

Info

Publication number
MX2020007467A
MX2020007467A MX2020007467A MX2020007467A MX2020007467A MX 2020007467 A MX2020007467 A MX 2020007467A MX 2020007467 A MX2020007467 A MX 2020007467A MX 2020007467 A MX2020007467 A MX 2020007467A MX 2020007467 A MX2020007467 A MX 2020007467A
Authority
MX
Mexico
Prior art keywords
phthalazinedione
solubilizing
dihydro
amino
solubilisate
Prior art date
Application number
MX2020007467A
Other languages
English (en)
Inventor
Ingo Saar
Wolfgang Brysch
Original Assignee
Metriopharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metriopharm Ag filed Critical Metriopharm Ag
Publication of MX2020007467A publication Critical patent/MX2020007467A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Abstract

La presente invención se refiere a un método para solubilizar 5-amino-2,3-dihidroftalazin-1,4-diona o sus sales, al solubilizado producido por este método, y los usos respectivos en una forma de dosificación farmacéutica. Se divulga un método de solubilización basado en fosfatidilcolinas.
MX2020007467A 2018-01-11 2019-01-10 Metodo para solubilizar 5 amino 2,3 dihidroftalazin 1,4 diona. MX2020007467A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18000019.2A EP3511325A1 (en) 2018-01-11 2018-01-11 Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
PCT/EP2019/000012 WO2019137825A1 (en) 2018-01-11 2019-01-10 Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione

Publications (1)

Publication Number Publication Date
MX2020007467A true MX2020007467A (es) 2020-09-14

Family

ID=61094178

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007467A MX2020007467A (es) 2018-01-11 2019-01-10 Metodo para solubilizar 5 amino 2,3 dihidroftalazin 1,4 diona.

Country Status (15)

Country Link
US (1) US20210061771A1 (es)
EP (2) EP3511325A1 (es)
JP (2) JP7446226B2 (es)
KR (1) KR20200108864A (es)
CN (1) CN111587243B (es)
AU (1) AU2019207332B2 (es)
BR (1) BR112020013847A2 (es)
CA (1) CA3084113A1 (es)
ES (1) ES2952192T3 (es)
HR (1) HRP20230766T1 (es)
HU (1) HUE062433T2 (es)
IL (1) IL275193B1 (es)
MX (1) MX2020007467A (es)
PL (1) PL3737668T3 (es)
WO (1) WO2019137825A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3290026A1 (en) * 2016-09-06 2018-03-07 Athenion AG Method for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents
US20220395547A1 (en) * 2019-11-08 2022-12-15 Vella Bioscience, Inc. Liposomal formulations for delivery of cannabinoids and methods of making thereof
EP4125802A1 (en) 2020-03-25 2023-02-08 MetrioPharm AG 5-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injury
CN116963738A (zh) 2020-12-02 2023-10-27 麦翠奥制药公司 用于SARS-CoV-2感染的后遗症的预防和治疗的鲁米诺
CN113384526A (zh) * 2021-08-03 2021-09-14 合肥医工医药股份有限公司 一种稳定的阿哌沙班口服溶液制剂及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857492A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Wasserhaltige Hautschutzpräparate zur Prävention von Hautschäden
US6441050B1 (en) * 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
DE20122900U1 (de) 2001-07-12 2009-12-03 Aquanova Ag Ubichinon Konzentrat
US8501232B2 (en) 2002-04-23 2013-08-06 Nanotherapeutics, Inc. Process of forming and modifying particles and compositions produced thereby
RU2245138C1 (ru) * 2003-10-21 2005-01-27 Общество с ограниченной ответственностью "Абидофарма" Способ лечения глазных заболеваний и глазные капли и глазная мазь для его осуществления
US20070104780A1 (en) 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
US20080145411A1 (en) * 2006-10-06 2008-06-19 Kaneka Corporation Composition of high absorbability for oral administration comprising oxidized coenzyme q10
US20080188540A1 (en) 2007-02-05 2008-08-07 Wyeth Pharmaceutical compositions containing substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
EP2328590A1 (en) 2008-08-18 2011-06-08 Nanotherapeutics, Inc. Topical hydrogel composition
PL231885B1 (pl) 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
US20100222584A1 (en) * 2009-02-06 2010-09-02 Bach Pharma, Inc. Pharmaceutical grade phthalazinediones, process for their preparation and pharmaceutical compositions containing them
EP2243517A1 (de) * 2009-04-20 2010-10-27 Dr. Straetmans GmbH Kosmetische oder dermatologische Zubereitung
CN105859634B (zh) 2010-03-01 2019-06-28 梅特里奥药品股份公司 5-氨基-2,3-二氢-(2,3-二氮杂萘)-1,4-二酮钠盐的晶型
US8871811B2 (en) * 2011-02-07 2014-10-28 Professional Compounding Centers of America, Ltd Permeation enhancers for topical formulations
ES2739194T3 (es) 2012-01-19 2020-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulación y método para aumentar la biodisponibilidad oral de fármacos
DE202012012130U1 (de) 2012-12-19 2014-03-21 Aquanova Ag Curcuminsolubilisat
US10258620B2 (en) * 2014-12-18 2019-04-16 Metriopharm Ag Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form
KR102535960B1 (ko) * 2016-02-16 2023-05-23 메트리오팜 아게 5-아미노-2,3-디하이드로프탈라진-1,4-디온의 새로운 결정질 형태
CN109071461B (zh) * 2016-02-16 2022-06-21 麦翠奥制药公司 制备5-氨基-2,3-二氢酞嗪-1,4-二酮结晶体的方法
EP3248602A1 (en) * 2016-05-26 2017-11-29 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
EP3290026A1 (en) * 2016-09-06 2018-03-07 Athenion AG Method for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents

Also Published As

Publication number Publication date
HRP20230766T1 (hr) 2023-10-27
IL275193B1 (en) 2024-04-01
WO2019137825A1 (en) 2019-07-18
JP2024059864A (ja) 2024-05-01
EP3511325A1 (en) 2019-07-17
AU2019207332B2 (en) 2023-09-28
CN111587243B (zh) 2024-04-12
JP7446226B2 (ja) 2024-03-08
RU2020118910A (ru) 2022-02-11
PL3737668T3 (pl) 2023-11-27
CN111587243A (zh) 2020-08-25
KR20200108864A (ko) 2020-09-21
AU2019207332A1 (en) 2020-06-18
EP3737668A1 (en) 2020-11-18
IL275193A (en) 2020-07-30
BR112020013847A2 (pt) 2021-03-02
US20210061771A1 (en) 2021-03-04
EP3737668B1 (en) 2023-06-07
ES2952192T3 (es) 2023-10-30
CA3084113A1 (en) 2019-07-18
EP3737668C0 (en) 2023-06-07
JP2021511301A (ja) 2021-05-06
HUE062433T2 (hu) 2023-11-28

Similar Documents

Publication Publication Date Title
MX2020007467A (es) Metodo para solubilizar 5 amino 2,3 dihidroftalazin 1,4 diona.
ZA202102696B (en) Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
SG10201805290YA (en) System and method for evaluation of used components
WO2018086591A8 (zh) 吡啶胺取代的杂三环化合物、其制法与医药上的用途
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
MY191581A (en) Anti-pd-1 antibodies
GB2541571A (en) Pharmaceutical compositions
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201808607SA (en) Medicine obtained by combining fxr agonist and arb
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
EA201891342A1 (ru) Изоиндольные соединения
MX2017013073A (es) Inhibidores de grelina o-aciltransferasa.
MY191462A (en) Circumcision aid
MX2017013072A (es) Inhibidores de grelina o-aciltransferasa.
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MD3288578T2 (ro) Compoziții pentru curățarea colonului și tratamentul tulburărilor gastrointestinale
MX2021005038A (es) Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas.
MX2019009200A (es) Composiciones y métodos para inhibir el reticulón 4.
MX2017013222A (es) Derivados de acido (s)-2'-vinil-abscisico.
IN2014MU00043A (es)
MD3707133T2 (ro) Compuși inhibitori de BTK
MX2020001928A (es) Proceso para la preparacion de tubulisinas e intermediarios de las mismas.